Citadel Advisors
VRDN icon

Citadel Advisors’s Viridian Therapeutics VRDN Stock Holding History

Citadel Advisors’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.27M Buy
64,700
+57,900
+851% +$1.72M ﹤0.01% 7142
2025
Q4 		$212K Buy
+6,800
New +$187K ﹤0.01% 10926
2025
Q2 		– Sell
-45,100
Closed -$608K – 15303
2025
Q1 		$608K Sell
45,100
-102,500
-69% -$1.75M ﹤0.01% 8047
2024
Q4 		$2.83M Buy
147,600
+100,400
+213% +$2.18M ﹤0.01% 4935
2024
Q3 		$1.07M Buy
47,200
+42,300
+863% +$692K ﹤0.01% 6741
2024
Q2 		$63.7K Buy
4,900
+3,800
+345% +$52.6K ﹤0.01% 11493
2024
Q1 		$19.3K Sell
1,100
-800
-42% -$15.5K ﹤0.01% 13041
2023
Q4 		$41.4K Sell
1,900
-28,600
-94% -$451K ﹤0.01% 11983
2023
Q3 		$468K Sell
30,500
-18,900
-38% -$361K ﹤0.01% 8211
2023
Q2 		$1.18M Buy
49,400
+45,700
+1,235% +$1.17M ﹤0.01% 6127
2023
Q1 		$94.1K Sell
3,700
-400
-10% -$12.8K ﹤0.01% 11355
2022
Q4 		$120K Buy
+4,100
New +$94.5K ﹤0.01% 10967

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Citadel Advisors's VRDN Position: Q1 2026 in Review

Citadel Advisors increased its Viridian Therapeutics (VRDN) stake by 241% in Q1 2026, buying an estimated $48.7M and bringing the position to 2,318,234 shares worth $45.3M. The position accounts for 0.01% of the portfolio, ranked #1449.

Citadel Advisors first reported a position in VRDN in Q4 2015 and has held it in 31 quarters since. 225 funds tracked by Wall St. Rank hold VRDN as of Q1 2026.

  • Citadel Advisors held 2,318,234 shares of Viridian Therapeutics worth $45.3M as of Q1 2026.
  • Citadel Advisors bought 1,638,540 Viridian Therapeutics shares in Q1 2026, an estimated $48.7M.
  • Viridian Therapeutics made up 0.01% of Citadel Advisors's portfolio in Q1 2026, its #1449 holding.
  • Citadel Advisors first reported a position in Viridian Therapeutics in Q4 2015 and has held it in 31 quarters since.
  • 225 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.